Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

But a recent coverage change by a major pharmacy benefit manager may force many to decide how much they're willing to pay for the drug or whether they want to try another weight loss option. As of ...

CVS Caremark alerted customers who used Zepbound in May, writing them in a letter, “This change is happening because there’s another covered medication that’s safe and effective for your ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay programs at $499 monthly ...

People who have had success with Zepbound may be able to file for an exception after the insurance coverage changes, but CVS Caremark has limited options to proactively plan for the change ...

As of July 1, CVS dropped Zepbound from preferred coverage for those covered by its pharmacy benefit manager, Caremark. Novo Nordisk A/S's Wegovy, a semiglutide injectable medicine, is now the ...

The coverage change applies to CVS Caremark’s most common formulary ... the subset of members who take weight-loss drugs chose Wegovy and Zepbound at roughly equivalent levels, CVS Health said.